Get started
Author

Detlef Albrecht

Prospective Randomized Controlled Trial of Extended-Release Oxybutynin Chloride and Tolterodine Tartrate in the Treatment of Overactive Bladder: Results of the OBJECT Study
2001 · Rodney A. Appell, Peter Sand, et al. · Mayo Clinic Proceedings · 281
Effect of pentosan polysulfate therapy on intravesical potassium sensitivity
2002 · C.Lowell Parsons, John Forrest, et al. · Urology · 77
Alloplastic Replacement of the Urinary Bladder
1996 · Dorothea Rohrmann, Detlef Albrecht, et al. · The Journal of Urology · 56
Efficacy and Safety of Oxybutynin in Children With Detrusor Hyperreflexia Secondary to Neurogenic Bladder Dysfunction
2005 · ISRAEL FRANCO, MARK HOROWITZ, et al. · The Journal of Urology · 55
Studies of Tin Ethyl Etiopurpurin Photodynamic Therapy of the Canine Prostate
2001 · STEVEN H. SELMAN, DETLEF ALBRECHT, et al. · The Journal of Urology · 50
Long-term safety of extended-release oxybutynin chloride in a community-dwelling population of participants with overactive bladder: A one-year study
2002 · Ananias Diokno, Peter Sand, et al. · International Urology and Nephrology · 46
DOUBLE-BLIND MULTICENTER STUDY COMPARING ALPROSTADIL α-CYCLODEXTRIN WITH MOXISYLYTE CHLORHYDRATE IN PATIENTS WITH CHRONIC ERECTILE DYSFUNCTION
1998 · Jacques Buvat, Pierre Costa, et al. · The Journal of Urology · 40
A Phase 1, Randomized, Open‐Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects
2020 · Detlef Albrecht, Mic Iwashima, et al. · Headache The Journal of Head and Face Pain · 28
PDF
Pharmacokinetics of prostaglandin E1 and its main metabolites after intracavernous injection and short-term infusion of prostaglandin E1 in patients with erectile dysfunction.
1997 · W Cawello, H Schweer, et al. · PubMed · 21
Pharmacokinetics of Prostaglandin E1 and Its Main Metabolites After Intracavernous Injection and Short-term Infusion of Prostaglandin E1 in Patients With Erectile Dysfunction
1997 · Willi Cawello, Horst Schweer, et al. · The Journal of Urology · 21
Pharmacokinetics of Tecarfarin and Warfarin in Patients with Severe Chronic Kidney Disease
2017 · Detlef Albrecht, Mintu Turakhia, et al. · Thrombosis and Haemostasis · 18
Oxybutynin Extended Release and Tolterodine Immediate Release
2004 · D Getsios, J J Caro, et al. · Clinical Drug Investigation · 18
A Double-Blind, Randomized, Parallel, Placebo-Controlled Study Examining the Effect of Cross-Linked Polyelectrolyte in Heart Failure Patients with Chronic Kidney Disease
2012 · Maria Rosa Costanzo, J. Thomas Heywood, et al. · European Journal of Heart Failure · 17
PDF
Effect of controlled‐release delivery on the pharmacokinetics of oxybutynin at different dosages: severity‐dependent treatment of the overactive bladder
2004 · Michael Preik, Detlef Albrecht, et al. · British Journal of Urology · 17
A randomized, open‐label, 5‐period crossover study evaluating the pharmacokinetics and safety of a single dose of intranasal dihydroergotamine (DHE) powder (STS101), intramuscular DHE mesylate, and liquid nasal spray DHE in healthy adults
2024 · Richard B. Lipton, Detlef Albrecht, et al. · Headache The Journal of Head and Face Pain · 12
Dihydroergotamine and triptan use to treat migraine during pregnancy and the risk of adverse pregnancy outcomes
2021 · Anick Bérard, Shannon Strom, et al. · Scientific Reports · 12
PDF
Pharmacokinetics and pharmacodynamics of tecarfarin, a novel vitamin K antagonist oral anticoagulant
2017 · Detlef Albrecht, David Ellis, et al. · Thrombosis and Haemostasis · 12
A randomised, double blind comparison of tecarfarin, a novel vitamin K antagonist, with warfarin
2016 · Richard P. Whitlock, Christopher B. Fordyce, et al. · Thrombosis and Haemostasis · 12
Treatment patterns and associated symptom improvement during six months of care for overactive bladder: A prospective, observational study
2002 · Timothy B. Boone, John W. Kusek, et al. · Clinical Therapeutics · 10
Long-Term (12-Month) Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine: Data from the Phase 3 Open-Label ASCEND Study
2024 · Stewart J. Tepper, Detlef Albrecht, et al. · CNS Drugs · 7
PDF
A Phase 1 dose-ranging study examining the effects of a superabsorbent polymer (CLP) on fluid, sodium and potassium excretion in healthy subjects
2014 · Lee W Henderson, Howard C Dittrich, et al. · BMC Pharmacology and Toxicology · 5
PDF
Dihydroergotamine for migraine: Evidence for multiple modes of action: The single molecule ‘combination’ product—A narrative review
2024 · Stewart J Tepper, Detlef Albrecht, et al. · Cephalalgia Reports · 2
882: Relationship of Self-Diagnosed Premature Ejaculation to Other Indicators of Male Sexual Function
2004 · Andrew R. McCullough, Scott Bull, et al. · The Journal of Urology · 2
PDF
Relationship of dihydroergotamine pharmacokinetics, clinical efficacy, and nausea—A narrative review
2024 · Richard B. Lipton, John A. Kollins, et al. · Headache The Journal of Head and Face Pain · 1
PDF
Cardiovascular Safety of STS101, A Novel Investigational DHE Nasal Powder Product: Initial Data from the ASCEND Study (P14-2.006)
2022 · Alan Rapoport, Shannon Strom, et al. · Neurology · 1
Works count: 43
Citation count: 824
H-index: 14
I10-index: 19
Year
Topic
Type